KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Net Margin (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Net Margin readings, the most recent being 9.19% for Q1 2026.

  • On a quarterly basis, Net Margin rose 372.0% to 9.19% in Q1 2026 year-over-year; TTM through Mar 2026 was 8.84%, a 2102.0% increase, with the full-year FY2025 number at 8.11%, up 2000.0% from a year prior.
  • Net Margin hit 9.19% in Q1 2026 for Teva Pharmaceutical Industries, down from 9.89% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 9.89% in Q4 2025 to a low of 54.79% in Q4 2022.
  • Median Net Margin over the past 5 years was 13.14% (2023), compared with a mean of 14.28%.
  • Biggest five-year swings in Net Margin: tumbled -2917bps in 2022 and later skyrocketed 5133bps in 2023.
  • Teva Pharmaceutical Industries' Net Margin stood at 54.79% in 2022, then surged by 94bps to 3.46% in 2023, then crashed by -181bps to 9.72% in 2024, then skyrocketed by 202bps to 9.89% in 2025, then decreased by -7bps to 9.19% in 2026.
  • The last three reported values for Net Margin were 9.19% (Q1 2026), 9.89% (Q4 2025), and 9.55% (Q3 2025) per Business Quant data.